MoonLake Immunotherapeutics (MEX:MLTXN) Total Assets: MXN7,219.82 Mil (As of Mar. 2026)


MEX:MLTXN MoonLake Immunotherapeutics MEX:MLTXN
30 GF Score
Price MXN305.30
! 3 Warning Signs
View Full Analysis

What is MoonLake Immunotherapeutics Total Assets?

MoonLake Immunotherapeutics MEX:MLTXN 30 Total Assets is MXN7,219.82 Mil as of Mar. 2026. GuruFocus rates MEX:MLTXN with a GF Score™ of 30/100. The stock has 3 warning signs investors should review.

MoonLake Immunotherapeutics's Total Assets for the quarter that ended in Mar. 2026 was MXN7,219.82 Mil.

During the past 12 months, MoonLake Immunotherapeutics's average Total Assets Growth Rate was 1.90% per year. During the past 3 years, the average Total Assets Growth Rate was 86.10% per year.

During the past 5 years, MoonLake Immunotherapeutics's highest 3-Year average Total Assets Growth Rate was 163.10%. The lowest was 86.10%. And the median was 124.60%.

Total Assets is connected with ROA %. MoonLake Immunotherapeutics's annualized ROA % for the quarter that ended in Mar. 2026 was -67.66%. Total Assets is also linked to Revenue through Asset Turnover. MoonLake Immunotherapeutics's Asset Turnover for the quarter that ended in Mar. 2026 was 0.00.

MoonLake Immunotherapeutics  (MEX:MLTXN) Total Assets Explanation

Total Assets is connected with ROA %.

MoonLake Immunotherapeutics's annualized ROA % for the quarter that ended in Mar. 2026 is

ROA %=Net Income (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=-5028.02/( (7642.213+7219.824)/ 2 )
=-5028.02/7431.0185
=-67.66 %

Note: The Net Income data used here is four times the quarterly (Mar. 2026) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

MoonLake Immunotherapeutics's Asset Turnover for the quarter that ended in Mar. 2026 is

Asset Turnover
=Revenue (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=0/( (7642.213+7219.824)/ 2 )
=0/7431.0185
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

MoonLake Immunotherapeutics Total Assets Related Terms

MoonLake Immunotherapeutics Total Assets Historical Data

* Premium members only.

The historical data trend for MoonLake Immunotherapeutics's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MoonLake Immunotherapeutics Total Assets Chart

MoonLake Immunotherapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Total Assets
198.62 1,498.13 8,937.62 9,967.63 7,642.21

MoonLake Immunotherapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10,459.50 8,663.24 7,600.64 7,642.21 7,219.82
MEX:MLTXN
30GF Score
MoonLake Immunotherapeutics MEX:MLTXN
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MoonLake Immunotherapeutics Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

MoonLake Immunotherapeutics's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (A: Dec. 2025 )+Total Liabilities (A: Dec. 2025 )
=5482.394+2159.82
=7,642.21

MoonLake Immunotherapeutics's Total Assets for the quarter that ended in Mar. 2026 is calculated as

Total Assets=Total Equity (Q: Mar. 2026 )+Total Liabilities (Q: Mar. 2026 )
=4580.739+2639.086
=7,219.83

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of MXN7,219.82 Mil mean?
MoonLake Immunotherapeutics (MEX:MLTXN) has a Total Assets of MXN7,219.82 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on MoonLake Immunotherapeutics and its competitors.
Is MoonLake Immunotherapeutics' Total Assets too high?
MoonLake Immunotherapeutics' current Total Assets is MXN7,219.82 Mil. Overall, MoonLake Immunotherapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does MoonLake Immunotherapeutics' Total Assets compare to AVBP and BCAX?
MoonLake Immunotherapeutics' Total Assets of MXN7,219.82 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on MoonLake Immunotherapeutics and its competitors. MoonLake Immunotherapeutics's current Total Assets is MXN7,219.82 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MoonLake Immunotherapeutics stock overvalued right now?
MoonLake Immunotherapeutics (MEX:MLTXN) has a current Total Assets of MXN7,219.82 Mil. The current Total Assets is MXN7,219.82 Mil. MoonLake Immunotherapeutics' overall GF Score™ is 30/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For MoonLake Immunotherapeutics (MEX:MLTXN), the current Total Assets is MXN7,219.82 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MoonLake Immunotherapeutics Business Description

Other Exchanges MLTX:USA
Address Dorfstrasse 29, Zug, CHE, 6300
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.
30GF Score

Get the complete analysis for MEX:MLTXN

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN305.30
Price